Skip to main content

Advertisement

SpringerLink
Log in

An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet’s disease in long-term remission

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

Although infliximab (IFX) decreases the risk of blindness due to refractory uveitis in patients with Behçet's disease (BD), there are no standard criteria for IFX switching or withdrawal. To evaluate the effect of IFX switching in patients with BD in long-term remission, a prospective, single-arm intervention trial was conducted, switching from IFX to cyclosporine A (CYA).

Study design

A prospective open-label study.

Methods

Eligible patients met the following criteria: administration of IFX without concomitant immunosuppressants for more than 5 years with no episodes of ocular attacks, no retinal vasculitis on fluorescein fundus angiography, negative C-reactive protein in serum, and no extraocular lesions at the time of IFX withdrawal. CYA 5 mg/kg/day was administered from 6 weeks after IFX withdrawal. The primary outcome was the rate of readministration of tumor necrosis factor inhibitors at 1 year after IFX withdrawal.

Results

Three of 45 BD patients treated with IFX for refractory uveitis were included in the study. At 1 year after withdrawal of IFX, no patient had experienced any ocular attacks or needed readministation of IFX. However, extraocular lesions, such as recurrent oral ulcers, folliculitis, and recurrent fevers, occurred in all patients. Liver or renal dysfunction, which may have been caused by CYA, was also observed in all patients.

Conclusions

Although no ocular attacks were observed for at least 1 year after IFX withdrawal, this prospective study indicates that IFX withdrawal should be considered carefully, even for patients in long term remission of ocular and extraocular lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The international criteria for Behcet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.

    Article  Google Scholar 

  2. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med. 1999;341:1284–91.

    Article  CAS  Google Scholar 

  3. Nussenblatt RB. Uveitis in Behcet’s disease. Int Rev Immunol. 1997;14:67–79.

    Article  CAS  Google Scholar 

  4. Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behcet’s disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;77:225–79.

    PubMed  PubMed Central  CAS  Google Scholar 

  5. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol. 2005;50:297–350.

    Article  Google Scholar 

  6. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77:808–18.

    PubMed  Google Scholar 

  7. Saravanan V, Hamilton J. Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opin Pharmacother. 2002;3:845–56.

    Article  CAS  Google Scholar 

  8. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet’s disease. Mediators Inflamm. 2002;11:87–93.

    Article  CAS  Google Scholar 

  9. Sayarlioglu M, Cinal A, Topcu N, Demirok A. Effect of infliximab on refractory uveitis in Behcet’s disease. Ann Pharmacother. 2004;38:901–2.

    Article  Google Scholar 

  10. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcet’s syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis. 2001;60:637.

    Article  CAS  Google Scholar 

  11. Sfikakis PP. Behcet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61(Suppl 2):ii51–3.

    Article  Google Scholar 

  12. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001;358:295–6.

    Article  CAS  Google Scholar 

  13. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.

    PubMed  CAS  Google Scholar 

  14. Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behcet’s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21:2.

    Article  Google Scholar 

  15. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210.

    Article  CAS  Google Scholar 

  16. Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, et al. Behcet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120–30.

    Article  CAS  Google Scholar 

  17. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161–4.

    Article  CAS  Google Scholar 

  18. Kawaguchi T, Kawazoe Y, Kamoi K, Miyanaga M, Takase H, Sugita S, et al. Clinical course of patients with Behcet’s uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75–80.

    Article  CAS  Google Scholar 

  19. Adan A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet’s disease after withdrawal of infusions. Int Ophthalmol. 2010;30:577–81.

    Article  Google Scholar 

  20. Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468–74.

    Article  CAS  Google Scholar 

  21. Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K, et al. Brief report: drug-free long-term remission in severe Behcet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol. 2017;69:2380–5.

    Article  CAS  Google Scholar 

  22. Keino H, Watanabe T, Nakayama M, Komagata Y, Fukuoka K, Okada AA. Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet’s disease. Br J Ophthalmol. 2020. https://doi.org/10.1136/bjophthalmol-2020-316892.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the JSPS under Grant 17K11428; the Ministry of Health, Labor and Welfare, Japan under Grant H29-Nanchi-Ippan-050.

Author information

Author notes

  1. Yasutsugu Ida and Masaki Takeuchi are first authors.

Authors and Affiliations

  1. Yokohama Minami Kyosai Hospital, Yokohama, Japan

    Yasutsugu Ida & Shigeru Kawano

  2. Department of Ophthalmology, Yokohama City University, Yokohama, Japan

    Yasutsugu Ida, Masaki Takeuchi, Mami Ishihara, Etsuko Shibuya, Takahiro Yamane, Yukiko Hasumi, Shigeru Kawano, Ikuko Kimura & Nobuhisa Mizuki

Authors
  1. Yasutsugu Ida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaki Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mami Ishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Etsuko Shibuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takahiro Yamane
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yukiko Hasumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shigeru Kawano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ikuko Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nobuhisa Mizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Takeuchi.

Ethics declarations

Conflicts of interest

Y. Ida, None; M. Takeuchi, None; M. Ishihara, None; E. Shibuya, None; T. Yamane, None; Y. Hasumi, None; S. Kawano, None; I. Kimura, None; N. Mizuki, None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Masaki Takeuchi

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ida, Y., Takeuchi, M., Ishihara, M. et al. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet’s disease in long-term remission. Jpn J Ophthalmol 65, 843–848 (2021). https://doi.org/10.1007/s10384-021-00872-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-021-00872-2

Keywords

Search

Navigation